Nav: Home

Future Science Group joins the AllTrials campaign

September 28, 2015

Future Science Group (FSG) today announced its support of the AllTrials campaign.

The AllTrials campaign aims to improve transparency and reporting of clinical trials. These aims align with those of Future Science Group (FSG), which believes that every trial should be conducted in a transparent and reproducible manner, ensuring that all research, even where negative or inconclusive, is both trustworthy and available to inform medical decision-making.

FSG requires all authors to follow the latest CONSORT and GPP3 guidelines. It is requested that trials are registered in a publicly accessible, free registry that is electronically searchable, open to prospective registrants and managed by a not-for-profit organization. Where trials are unregistered, FSG requires a clear statement and explanation to be included in the article.

"It's great news that FSG has joined AllTrials, and is introducing practical measures to raise awareness and improve the registration practice of researchers, " commented James Cockerill, Campaigns Manager, Sense About Science. "We are calling for every clinical trial--past, present and future--to be registered, and their results reported. It's time for the whole research community to embrace clinical trial transparency, and we welcome efforts from publishers and journals that demonstrate leadership and do what they can to help fix the problem."

"Researchers are sometimes deterred from submitting negative or inconclusive data to journals, as STM publishers have traditionally not prioritized this research for publication," explained Laura Dormer, Senior Manager (Commissioning & Journal Development) at FSG. "We believe that the results of all well-conducted research should be available, and our support for AllTrials is another way of demonstrating our commitment to this."
If you are interested in submitting a trial report to a journal published by Future Science Group, please contact us here -

About Future Science Group

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. Both publish eBooks and journals. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites includes Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.

The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. | |

Future Science Group

Related Clinical Trials Articles:

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.
Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.
Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.
Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.
When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.
More Clinical Trials News and Clinical Trials Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...